A decade of cerebrospinal fluid biomarkers for Alzheimer's disease in Belgium

Journal of Alzheimer's Disease

Volumn 54, Issue 1, 2016, Pages 383-395

  Somers, Charisse ^a   Struyfs, Hanne ^a   Goossens, Joery ^a   Niemantsverdriet, Ellis ^a   Luyckx, Jill ^a   De Roeck, Naomi ^a   De Roeck, Ellen ^a   De Vil, Bart ^a   Cras, Patrick ^a,c   Martin, Jean Jacques ^a   De Deyn, Peter Paul ^a,b   Bjerke, Maria ^a   Engelborghs, Sebastiaan ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Memory Clinic   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Alzheimer's disease; Amyloid; Biomarkers; Cerebrospinal fluid; Dementia; Diagnosis; Mild cognitive impairment; Neuropathology; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PROTEIN 14 3 3; TAU PROTEIN; THREONINE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BELGIUM; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELISA KIT; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NEUROCHEMISTRY; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSYCHOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DEMENTIA ASSESSMENT; DIFFERENTIAL DIAGNOSIS; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BELGIUM; BIOMARKERS; COGNITIVE DYSFUNCTION; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS AND DEMENTIA TESTS; MIDDLE AGED; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84984706079     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-151097     Document Type: Article

References (52)

1. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomark-ers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234.
2. Engelborghs S, De Vreese K, Van de Casteele T, Van-derstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29, 1143-1159.
3. 42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248-253.
4. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Par-netti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385.
5. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Igbal K, Pottel H, Vanmechelen E, Vander-stichele H (1999) Improved discrimination of AD patients using fj-amyloid(1-42) and tau levels in CSF. Neurology 52, 1555.
6. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund L, Freund-Levi Y, Tsolaki M, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, 619-627.
7. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
8. Le Bastard N, Coart E, Vanderstichele H, Martin J, Engelborghs S (2013) Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. J Alzheimers Dis 33, 117-131.
9. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo Mc, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
10. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bate-man R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol 13, 614-629.
11. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
12. Bier J, Verschraegen J, Vandenberghe R, Guillaume B, Picard G, Otte G, Mormont E, Gilles C, Segers K, Sieben A, Thiery E, Ventura M, De Deyn P, Deryck O, Versijpt J, Salmon E, Engelborghs S, Ivanoiu A (2015) Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: A BeDeCo survey. Acta Neurol Belg 115, 547-555.
13. Le Bastard N, Martin J, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S (2010) Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging 31, 1867-1876.
14. Struyfs H, Niemantsverdriet E, Goossens J, Fransen E, Martin J, De Deyn PP, Engelborghs S (2015) Cerebrospinal fluid P-Tau181P: Biomarker for improved differential dementia diagnosis. Front Neurol 6, 138.
15. Engelborghs S (2013) Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Rev Neurol (Paris) 169, 709-714.
16. Niemantsverdriet E, Feyen BFE, Le Bastard N, Martin J, Goeman J, De Deyn PP, Engelborghs S (2015) Overdiag-nosing vascular dementia using structural brain imaging for dementia work-up. J Alzheimers Dis 45, 1039-1043.
17. Engelborghs S, Le Bastard N (2012) The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. J Neurol Sci 322, 197-199.
18. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
19. Cuadrado-Corrales N, Jimenez-Huete A, Albo C, Hor-tigüela R, Vega L, Cerrato L, Sierra-Moros M, Rabano A, de Pedro-Cuesta J, Calero M (2006) Impact of the clinical context on the 14-3-3 test for diagnosis of sporadic CJD. BMC Neurol 6, 25.
20. Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, Windl O, Kretzschmar HA, Weber T (1998) Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 43, 32.
21. Van Everbroeck B (2003) A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 74, 1210.
22. Van Everbroeck B, Boons J, Cras P (2005) 14-3-3-y-isoform detection distinguishes sporadic Creutzfeldt-Jacob disease from other dementias. J Neurol Neurosurg Psychiatry 76, 100-102.
23. Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Marien P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S (2014) Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: A longitudinal study. J Alzheimers Dis 42, 1239-1250.
24. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Hee-gaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Kaeser SA, Lachno DR, Lleo A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman RA, Rosenmann H, Sancesario G, Schroder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, Alzheimer's Association QC Program Work Group (2013) CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 9, 251-261.
25. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT; National Institute on Aging; Alzheimer's Association (2011) National Institute on Aging-Alzheimer's Association guidelines for the neu-ropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 123, 1-11.
26. Cairns NJ, Bigio EH, Mackenzie IRA, Neumann M, Hatan-paa KJ, White CL3rd, Schneider JA, Grinberg LT, Halliday G, Duyckaerts C, Lowe JS, Holm IE, Tolnay M, Okamoto K, Yokoo H, Murayama S, Woulfe J, Munoz DG, Dickson DW, Ince PG, Trojanowski JQ, Mann DM; Consortium for Frontotemporal Lobar Degeneration (2007) Neuropatho-logic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114, 22.
27. Mackenzie IRA, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Jaros E, Perry RH, Trojanowski JQ, Mann DM, Lee VM (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122, 111-113.
28. Mackenzie IRA, Neumann M, Bigio EH, Cairns NJ, Ala-fuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM (2009) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: An update. Acta Neuropathol 119, 1-4.
29. Markesbery WR (1998) Neuropathology of Dementing Disorders, Oxford Univ Press, London.
30. Lleo A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, Ghidoni R, Lewczuk P, Jeromin A, Winblad B, Tsolaki M, Mroczko B, Visser PJ, Santana I, Svenningsson P, Blennow K, Aarsland D, Molinuevo JL, Zetterberg HH, Mollenhauer B (2014) Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol 11, 41-55.
31. Tang W, Huang Q, Wang Y, Wang Z, Yao Y (2014) Assessment of CSF Afj42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies. J Neurol Sci 345, 26-36.
32. Meiner Z, Kahana E, Baitcher F, Korczyn AD, Chapman J, Cohen OS, Milo R, Aharon-Perez J, Abramsky O, Gabizon R, Rosenmann H (2010) Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel. J Neurol 258, 255.
33. Mukaetova-Ladinska EB, Monteith R, Perry EK (2010) Cerebrospinal fluid biomarkers for dementia with Lewy bodies. Int J Alzheimers Dis 2010, 536538.
34. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeck-hoven C, De Deyn PP (2007) No association of CSF biomarkers with APOEe4, plaque and tangle burden in definite Alzheimer's disease. Brain 130, 2320.
35. Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, De Leenheir E, Luyckx J, Martin JJ, Van Broeckhoven C, Engelborghs S (2013) Amyloid pathology influences Afj1-42 cerebrospinal fluid levels in dementia with Lewy bodies. J Alzheimers Dis 35, 137-146.
36. Slaets S, Le Bastard N, Martin J, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S (2013) Cerebrospinal fluid Afj1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis 36, 759-767.
37. Spies PE, Slats D, Sjogren JMC, Kremer BPH, Verhey FRJ, Rikkert MG, Verbeek MM (2010) The cerebrospinal fluid amyloid 342/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res 7, 470.
38. Sauvee M, Didier Laurent G, Latarche C, Escanye M, Olivier J, Malaplate-Armand C (2014) Additional use of Abeta42/Abeta40 ratio with cerebrospinal fluid biomarkers P-Tau and Abeta42 increases the level of evidence of Alzheimer's disease pathophysiological proces in routine practice. J Alzheimers Dis 41, 377-386.
39. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J (2015) Amyloid-fj 42/40 cerebrospinal fluid concentration ratio in the diagnosis of Alzheimer's disease: Validation of two novel assays. J Alzheimers Dis 43, 183-191.
40. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Schel-tens P, Verhey FRJ, Visser PJ, Amyloid Biomarker Study Group, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Forster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gomez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Kohler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleo A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonca A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergard HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Par-netti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodriguez-Rodriguez E, Roe CM, Rot U, Rowe CC, Ruther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schroder J, Schutte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin AK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H (2015) Prevalence of cerebral amyloid pathology in persons without dementia. JAMA 313, 1924-1915.
41. Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C, De Deyn PP, Streffer JR, Mercken M, Engelborghs S (2015) Diagnostic accuracy of cerebrospinal fluid amyloid-fj isoforms for early and differential dementia diagnosis. J Alzheimers Dis 45, 813-822.
42. Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin J, De Deyn PP, Engelborghs S (2014) Increased CSF a-synuclein levels in Alzheimer's disease: Correlation with taulevels. Alzheimers Dement 10(S), S290-S298.
43. Simonsen AH, Kuiperij B, Ali El-Agnaf OM, Engelborghs S, Herukka SK, Parnetti L, Rektorova I, Vanmechelen E, Kapaki E, Verbeek M, Mollenhauer B (2016) The utility of a-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature. Biomark Med 10, 19-34.
44. Goossens J, Vanmechelen E, Trojanowski JQ, Lee VM, Van Broeckhoven C, van der Zee J, Engelborghs S (2015) TDP-43 as a possible biomarker for frontotemporal lobar degeneration: A systematic review of existing antibodies. Acta Neuropathol Commun 3, 15.
45. Mattsson N, Zetterberg H, Blennow K (2010) Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease. Int J Alzheimers Dis [2010], pii: 610613.
46. Niemantsverdriet E, Goossens J, Struyfs H, Martin J, Goe-man J, De Deyn PP, Vanderstichele H, Engelborghs S (2016) Diagnostic impact of cerebrospinal fluid biomarker variability in Alzheimer's disease. J Alzheimers Dis 51, 97-106.
47. Le Bastard N, De Deyn PP, Engelborghs S (2015) Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem 61, 734-743.
48. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, Andreasen N, Zetterberg H, Andreas-son U, Blennow K (2010) Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010, pii: 986310.
49. Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, Teunissen CE, Parnetti L (2014) The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 10, 1-10.
50. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Llado A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7, 386-395. e6.
51. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 8, 65-73.
52. Bjerke M, Andreasson U, Kuhlmann J, Portelius E, Pannee J, Lewczuk P, Umek RM, Vanmechelen E, Vanderstichele H, Stoops E, Lewis J, Vandijck M, Kostanjevecki V, Jeromin A, Salamone SJ, Schmidt O, Matzen A, Madin K, Eichenlaub U, Bittner T, Shaw LM, Zegers I, Zetterberg H, Blennow K (2016) Assessing the commutability of reference material formats for the harmonization of amyloid beta measurements. Clin Chem Lab Med 54, 1177-1191.